To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of
single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK
and PD of multiple doses of KHK.

A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

Type 2 Diabetes Mellitus (T2DM)

ALN-KHK

Clinical Trial Site

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2-Part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-KHK in Overweight to Obese Adult Healthy Volunteers and Multiple Dose ALN-KHK in Obese Patients With Type 2 Diabetes Mellitus (T2DM)

Participants will be administered a single dose of ALN-KHK.

Participants will be administered a single dose of placebo.

Participants will be administered a multiple doses of ALN-KHK.

Participants will be administered a multiple doses of placebo.